Lakefront Biotherapeutics (LKFT) Capital Expenditures (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Capital Expenditures for 13 consecutive years, with -$144001.7 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 97.31% year-over-year to -$144001.7; the TTM figure through Mar 2026 stood at $21.9 million (up 33.66% YoY), while the FY2025 annual figure was $16.0 million, down 10.72% from the prior year.
• Capital Expenditures declined to -$144001.7 in Q1 2026 per LKFT's latest filing, from $30.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $48.2 million in Q4 2022 and bottomed at -$10.3 million in Q1 2022.
• Historically, Capital Expenditures has averaged $7.7 million across 5 years, with a median of -$3.6 million in 2024.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 33.46% — and 2026, when it surged 97.31%.
• Lakefront Biotherapeutics' Capital Expenditures stood at $48.2 million in 2022, then slumped by 33.46% to $32.0 million in 2023, then declined by 6.55% to $29.9 million in 2024, then rose by 0.32% to $30.0 million in 2025, then plunged by 100.48% to -$144001.7 in 2026.
• Business Quant data shows LKFT's Capital Expenditures at -$144001.7 in Q1 2026, $30.0 million in Q4 2025, and -$3.3 million in Q3 2025.